Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2)
- 28 September 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 73 (2), 726-737
- https://doi.org/10.1002/hep.31314
Abstract
Background and Aims Portopulmonary hypertension (POPH) was previously associated with a single-nucleotide polymorphism (SNP) rs7175922 in aromatase (cytochrome P450 family 19 subfamily A member 1 [CYP19A1]). We sought to determine whether genetic variants and metabolites in the estrogen signaling pathway are associated with POPH. Approach and Results We performed a multicenter case-control study. POPH patients had mean pulmonary artery pressure >25 mm Hg, pulmonary vascular resistance >240 dyn-sec/cm(-5), and pulmonary artery wedge pressure <= 15 mm Hg without another cause of pulmonary hypertension. Controls had advanced liver disease, right ventricular (RV) systolic pressure <40 mm Hg, and normal RV function by echocardiography. We genotyped three SNPs inCYP19A1andCYP1B1using TaqMan and imputed SNPs in estrogen receptor 1 using genome-wide markers. Estrogen metabolites were measured in blood and urine samples. There were 37 patients with POPH and 290 controls. Mean age was 57 years, and 36% were female. The risk allele A in rs7175922 (CYP19A1) was significantly associated with higher levels of estradiol (P = 0.02) and an increased risk of POPH (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.12-4.91;P = 0.02) whereas other SNPs were not. Lower urinary 2-hydroxyestrogen/16-alpha-hydroxyestrone (OR per 1-ln decrease = 2.04; 95% CI, 1.16-3.57;P = 0.01), lower plasma levels of dehydroepiandrosterone-sulfate (OR per 1-ln decrease = 2.38; 95% CI, 1.56-3.85;P < 0.001), and higher plasma levels of 16-alpha-hydroxyestradiol (OR per 1-ln increase = 2.16; 95% CI, 1.61-2.98;P < 0.001) were associated with POPH. Conclusions Genetic variation in aromatase and changes in estrogen metabolites were associated with POPH.Funding Information
- Biotechnology and Biological Sciences Research Council (BBSRC: BB/N503691/1)
- National Heart, Lung, and Blood Institute (K23 HL141584, K24 HL103844, R01 HL113988)
This publication has 41 references indexed in Scilit:
- Activity of the Estrogen-Metabolizing Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary Arterial HypertensionCirculation, 2012
- BMPR2 expression is suppressed by signaling through the estrogen receptorBiology of Sex Differences, 2012
- MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypesGenetic Epidemiology, 2010
- Comparison of Liquid Chromatography-Tandem Mass Spectrometry, RIA, and ELISA Methods for Measurement of Urinary EstrogensCancer Epidemiology, Biomarkers & Prevention, 2010
- Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Dehydroepiandrosterone Stimulates Phosphorylation of FoxO1 in Vascular Endothelial Cells via Phosphatidylinositol 3-Kinase- and Protein Kinase A-dependent Signaling Pathways to Regulate ET-1 Synthesis and SecretionOnline Journal of Public Health Informatics, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesAmerican Journal of Human Genetics, 2007
- Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertensionCardiovascular Research, 2007
- Hemodynamics and survival of patients with portopulmonary hypertensionLiver Transplantation, 2005
- A model to predict survival in patients with end-stage liver diseaseHepatology, 2001